Reboxetine maintenance treatment in children with attention-deficit/ hyperactivity disorder: A long-term follow-up study

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 6, 2007, Pages 803-811

  Toren, Paz ^a,b,e   Ratner, Sharon ^a   Weizman, Abraham ^b,c   Lask, Michal ^a   Ben Amitay, Galit ^a,b   Laor, Nathaniel ^a,b,d  

^a TEL AVIV COMMUNITY MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

REBOXETINE;

ABDOMINAL PAIN; ADOLESCENT; AGITATION; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD ANALYSIS; BLOOD PRESSURE; BODY HEIGHT; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART RATE; HUMAN; LABORATORY TEST; MAINTENANCE THERAPY; MALE; MORNING DOSAGE; OPEN STUDY; RATING SCALE; SCHOOL CHILD; SEDATION; SELF REPORT; SIDE EFFECT; SUICIDAL IDEATION; SUICIDE ATTEMPT; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BODY WEIGHT; CHILD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MORPHOLINES; PARENTS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SUICIDE;

EID: 38549162079     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.0145     Document Type: Article

References (25)

1. Aguglia E: Reboxetine in the maintenance therapy of depressive disorder in the elderly: A long-term open study. Int J Geriatr Psychiatry 15:784-793, 2000.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSMIV-TR). Washington (DC), American Psychiatric Association, 2000.
3. Avenoso A, Facciola G, Scordo MG, Spina E: No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers. Ther Drug Monit 21:577-579, 1999.
4. Cocchiara G, Battaglia R, Pevarello P, Strolin-Benedetti M: Comparison of disposition and of the metabolic pattern of reboxetine, a new antidepressant, in the rat, dog, monkey and man. Eur J Drug Metab Pharmacokinet 16:231-239, 1991.
5. Conners CK, Barkley RA: Rating scales and checklists for child psychopharmacology. Psychopharmacol Bull 21:809-843, 1985.
6. Dostert P, Benedetti MS, Poggesi I: Review of the pharmacokinetics and metabolism of reboxetine, a selective norepinephrine reuptake inhibitor. Eur Neuropsychopharmacol 7:S23-S35, 1997.
7. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale IV: Checklists, Norms, and Clinical Interpretation. New York, Guilford, 1998.
8. th, 2004.
9. Fleishaker JC, Francom SF, Herman BD, Knuth DW, Azie NE: Lack of effect of reboxetine on cardiac repolarization. Clin Pharmacol Ther 70:261-269, 2001.
10. nd edition, 2000.
11. Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda (Maryland), U.S. Department of Health, Education, and Welfare, 1976.
12. Kasper S, El Giamal N, Hilger E: Reboxetine: The first selective norepinephrine re-uptake inhibitor. Expert Opin Pharmacother 1:771-782, 2000.
13. Mozes T, Meiri G, Ben-Amity G, Sabbagh M, Weizman A: Reboxetine as an optional treatment for hyperkinetic conduct disorder: A prospective open-label trial. J Child Adolesc Psychopharmacol 15:259-269, 2005.
14. MTA Cooperative Group: National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: Changes in effectiveness and growth after the end of treatment. Pediatrics 113:762-769, 2004.
15. Mucci M: Reboxetine: A review of antidepressant tolerability. J Psychopharmacol 11:S33-S37, 1997.
16. Rampello L, Alvano A, Chiechio S, Raffaele R, Vecchio I, Malaguarnera M: An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression: A random, placebo-controlled study. Arch Gerontol Geriatrics 40:275-285, 2005.
17. Ratner S, Laor N, Bronstein Y, Weizman A, Toren P: Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 44:428-433, 2005.
18. Riva M, Brunello N, Rovescalli AC, Galimberti R, Carminati P, Pozzi O, Ricciardi S, Roncucci R, Rossi A, Racagni G: Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: Behavioural and biochemical studies. J Drug Dev 1:243-254, 1989.
19. Schatz AM, Ballantyne AO, Trauner DA: Sensitivity and specificity of a computerized test of attention in the diagnosis of attention-deficit/ hyperactivity disorder. Assessment 8:357-365, 2001.
20. Shanee N, Apter A, Weizman A: Psychometric properties of the K-SADS-PL in an Israeli adolescent clinical population. Isr J Psychiatry Relat Sci 34:179-187, 1997.
21. Spivak B, Vered Y, Yoran-Hagesh R, Averbuch E, Mester R, Graf E, Weizman A: Circulatory levels of catecholamines, serotonin and lipids in attention deficit hyperactivity disorder. Acta Psychiatr Scand 99:300-304, 1999.
22. Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R: Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 60:400-406, 1999.
23. Wienkers LC, Allievi C, Hauer MJ, Wynalda MA: Cytochrome P-450 mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos 27:1334-1340, 1999.
24. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, Hyslop WP, Fraklin S, Porsolt RD, Bonsignori A, Carfagna N, McArthur RA: Reboxetine: A pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47:818-829, 2000.
25. Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R: Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 60:400-406, 1999.